INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Innoviva, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$21.08+0.30 (+1.44%)
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- 5.2
- Dividend yield
- –
Share price
+$3.81 (+22.06%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Innoviva, Inc. grew revenue 18.8% to $440.00M over the twelve months to Jun 30, 2026. Operating income fell 7.9% to $162.58M, moving the operating margin from 47.7% to 36.9%. Free cash flow was $189.44M, down 5.4% from a year earlier.
Revenue
$440.00M
+18.8% vs. a year earlier
Operating income
$162.58M
-7.9% vs. a year earlier
Free cash flow
$189.44M
-5.4% vs. a year earlier
EPS, diluted
$4.08
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.55B
- P/E ratio
- 5.2
- Price to sales
- 3.52
- Price to book
- 1.25
- Dividend yield
- –
- Free cash flow yield
- 12.24%
Fundamentals
- Revenue
- $440.00M
- EPS, diluted
- $4.08
- Free cash flow
- $189.44M
- Book value per share
- $16.80
- Diluted shares
- 73M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$440.00M+18.8% YoY
Gross profit
$317.66M+3.3% YoY
Operating income
$162.58M-7.9% YoY
EPS, diluted
$4.08
Free cash flow
$189.44M-5.4% YoY
Reported periodTrailing twelve months